ICON Public Limited Company (ICLR) |
| 169.31 3.62 (2.18%) 09-11 16:00 |
| Open: | 165.68 |
| High: | 175.63 |
| Low: | 165.68 |
| Volume: | 1,710,002 |
| Market Cap: | 12,964(M) |
| PE Ratio: | 13.81 |
| Exchange: | NASDAQ |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 211.28 |
| Resistance 1: | 180.89 |
| Pivot price: | 166.05 |
| Support 1: | 165.94 |
| Support 2: | 156.71 |
| 52w High: | 203.91 |
| 52w Low: | 66.57 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
| EPS | 0.640 |
| Book Value | 121.550 |
| PEG Ratio | 0.50 |
| Gross Profit | 25.664 |
| Profit Margin (%) | 0.33 |
| Operating Margin (%) | 9.41 |
| Return on Assets (ttm) | 1.0 |
| Return on Equity (ttm) | 0.3 |
Thu, 10 Sep 2026
ICON PLC (NASDAQ: ICLR) Releases Unaudited Interim Financial Statements in September 9 Filing - kalkinemedia.com
Fri, 28 Aug 2026
How ICON’s Mixed Q1 Earnings and Reaffirmed 2026 Outlook Could Impact ICON (ICLR) Investors - Sahm
Wed, 29 Jul 2026
ICON Public Limited Company (ICLR) Surges on Net Book-to-Bill Strength - Yahoo Finance
Tue, 28 Jul 2026
ICON plc rises after Anthropic deal, IQVIA earnings (ICLR:NASDAQ) - Seeking Alpha
Tue, 23 Jun 2026
ICON Public Limited Company ($ICLR) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Tue, 02 Jun 2026
Is ICON Stock Finally Priced for Recovery After a $3.9B Backlog Cut and a Q4 2025 EPS Miss? - TIKR.com
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |